$YDES News

YD Bio Limited Reports Full Year 2025 Financial Results

YD Bio and EG BioMed Jointly Launch Nationwide Telehealth Platform to Accelerate Commercialization of Cancer Detection and Decentralized Clinical Services Across the United States

YD Bio Limited CEO Dr. Ethan Shen Details Strategic Roadmap for Integrated Oncology Ecosystem

YD Bio Limited Announces Strategic Partnership with YC Biotech Co., Ltd. to Establish a Taiwan-U.S. Dual-Core Regulatory Platform

YD Bio's Subsidiary Enters Into Master Strategic Alliance Agreement With YC Biotech To Establish Taiwan-U.S. Dual-Core Regulatory Platform

YD Bio Limited Enters into Binding Letter of Intent to Acquire Safe Save Medical Cell Sciences & Technology Co., Ltd., Bolstering Leadership in Advanced Immunocell Therapy

YD Bio Limited Signs Binding LOI To Acquire Safe Save Medical Cell Sciences & Technology; Co Intends To Acquire 100% Of Equity Interest For Consideration Of $26.87M

YD Bio Limited Signs Binding LOI To Acquire Safe Save Medical Cell Sciences & Technology; Co Intends To Acquire 100% Of Equity Interest For Consideration Of $26.87M

YDES: YD Biopharma is an integrated biotechnology company that is poised to have a transformational year as it expands business operations.

YDES is A Biotechnology Company on the Move

YD Bio shares are trading lower. The company announced that it has entered into a Memorandum of Understanding to merge with EG BioMed.

YD Bio Enters into MOU to Merge with EG BioMed, Advancing DNA Methylation–Driven AI Platforms for Cancer Diagnostics and Drug Development

YD Bio Strikes Memorandum Of Understanding To Merge With EG BioMed; Financial Terms Not Disclosed

YD Bio Limited Announces Major Milestones and Unveils Robust 2026 Clinical and Commercial Roadmap

YD Bio Limited Expands U.S. Presence with Newly Planned California Facilities and Operations Center

YD Bio Announces Latest Plans For New Sites, U.S. Operations Center In California

YD Bio Limited Showcases Its Innovative Diagnostic and Precision Medicine Portfolios at the 9th Healthcare EXPO TAIWAN

YD Bio Limited Expands OkaiDx™ Testing Portfolio to Pancreatic and Colorectal Cancer Detection Across the U.S. and Provides Clinical Research Update on Pancreatic Cancer Early Detection

YD Bio shares are trading higher after the company announced it obtained 510(k) clearance and OTC monograph compliance. The company announced that it, along with 3D Global Biotech, is planning a small clinical trial in Taiwan to evaluate dry eye disease.

Reported Earlier: YD Bio Through Its Partner 3D Global Biotech, Announces Exovisse Contact Lenses Has Obtained FDA 510(k) Clearance As A Class II Medical Device, Enabling Legal Marketing In The U.S.; Its Exovisse Artificial Tears Have Been Developed In Compliance With The FDA OTC Final Monograph M018